PH-sensitive nanoparticles of curcumin-celecoxib combination: Evaluating drug synergy in ulcerative colitis model

Journal of Pharmaceutical Sciences

Volumn 103, Issue 2, 2014, Pages 687-696

  Gugulothu, Dalapathi ^a   Kulkarni, Aditya ^a   Patravale, Vandana ^a   Dandekar, Prajakta ^a  

^a INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Colonic drug delivery; Drug delivery systems; Drug targeting; Nanoparticles; Natural products; Oral drug delivery; Polymeric drug carrier; Site specific delivery; Targeted drug delivery

Indexed keywords

CELECOXIB; CURCUMIN; EUDRAGIT; NANOCARRIER; POLYMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FREEZE DRYING; MALE; NONHUMAN; PH; RAT; ULCERATIVE COLITIS;

COLONIC DRUG DELIVERY; DRUG DELIVERY SYSTEMS; DRUG TARGETING; NANOPARTICLES; NATURAL PRODUCTS; ORAL DRUG DELIVERY; POLYMERIC DRUG CARRIER; SITE-SPECIFIC DELIVERY; TARGETED DRUG DELIVERY;

ALGORITHMS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL AVAILABILITY; COLITIS, ULCERATIVE; COLON; CURCUMIN; CYCLOOXYGENASE 2 INHIBITORS; DRUG COMBINATIONS; DRUG COMPOUNDING; DRUG SYNERGISM; ELECTROCHEMISTRY; EXCIPIENTS; FREEZE DRYING; HYDROGEN-ION CONCENTRATION; LIPID PEROXIDATION; MALE; NANOPARTICLES; PARTICLE SIZE; PEROXIDASE; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES; SUPEROXIDE DISMUTASE;

EID: 84895923619     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23828     Document Type: Article

References (39)

1. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. 2012. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterol 142 (1):46-54.
2. Kane SV. 2006. Systematic review: Adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 23(5):577-585.
3. Celasco G, Papa A, Jones R, Moro L, Bozzella R, Surace MM, Naccari GC, Gasbarrini G. 2010. Clinical trial: Oral colon-release parnaparin sodium tablets (CB-01-05 MMX) for active left-sided ulcerative colitis. Aliment Pharmacol Ther 31(3):375-386.
4. Hanauer SB. 2004. Review article: The long-term management of ulcerative colitis. Aliment Pharmacol Ther 20(4):97-101.
5. Bebb JR, Scott BB. 2004. How effective are the usual treatments for ulcerative colitis? Aliment Pharmacol Ther 20(2):143-149.
6. Sandborn WJ, Stenson WF, Brynskov J, orenz RGL, Steidle GM, Robbins JL, Kent JD, Bloom BJ. 2006. Safety of celecoxib in patients with ulcerative colitis in remission: A randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol 4(2):203-211.
7. Jurenka JS. 2009. Anti-inflammatory properties of curcumin, a major constituent of curcuma longa: A review of preclinical and clinical research. Altern Med Rev 14(2):141-153.
8. Taylor RA, Leonard MC. 2011. Curcumin for inflammatory bowel disease: A review of human studies. Altern Med Rev 16(2):152-156.
9. Dandekar PP, Jain R, Kumar C, Subramanian S, Samuel G, Venkatesh M, Patravale V. 2009. Curcumin loaded pH-sensitive nanoparticles for the treatment of colon cancer. J Biomed Nanotechnol 5(5):445-455.
10. Lev-Ari S, Strier L, Kazanov D, Madar-Shapiro L, Dvory-Sobol H, Pinchuk I, Marian B, Lichtenberg D, Arber N. 2005. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Clin Cancer Res 11(18):6738-6744.
11. Lev-Ari S, Strier L, Kazanov D, Elkayam O, Lichtenberg D, Caspi D, Arber N. 2006. Curcumin synergistically potentiates the growthinhibitory and pro-ppoptotic effects of celecoxib in osteoarthritis synovial adherent cells. Rheumatol 45(2):171-177.
12. Hong J, Bose M, Ju J, Ryu JH, Chen X, Sang S, Lee MJ, Yang CS. 2004. Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: Effects on cytosolic phospholipase A (2), cyclooxygenases and 5-lipoxygenase. Carcinogenesis 25(9):1671-1679.
13. Jaggi R, Wurgler U, Grandjean F, Weiser M. 2004. Dual inhibition of 5-lipoxygenase/cyclooxygenase by a reconstituted homeopathic remedy; possible explanation for clinical efficacy and favourable gastrointestinal tolerability. Inflamm Res 53(4):150-157.
14. Morsy MA, El-Moselhy MA. 2013. Mechanisms of the protective effects of curcumin against indomethacin-induced gastric ulcer in rats. Pharmacology 91(5-6):267-274.
15. Sostres C, Gargallo CJ, Arroyo MT, Lanas A. 2010. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol 24(2):121-132.
16. Vong LB, Tomita T, Yoshitomi T, Matsui H, Nagasaki Y. 2012. An orally administered redox nanoparticle that accumulates in the colonic mucosa and reduces colitis in mice. Gastroenterology 143(4):1027-1036.
17. Whelton A. 2000. Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non-NSAID analgesics. Am J Ther 7(2):63-74.
18. Gugulothu DB, Patravale VB. 2012. A new stability-indicating HPLC method for simultaneous determination of curcumin and celecoxib at single wavelength: an application to nanoparticulate formulation. Pharm Anal Acta 3(4):157.
19. Coco R, Plapied L, Pourcelle V, Jérôme C, Brayden DJ, Schneider YJ, Preat V. 2013. Drug delivery to inflamed colon by nanoparticles: Comparison of different strategies. Int J Pharm 440(1):3-12.
20. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL. 1989. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96(3):795-803.
21. Guo X, Liu ES, Ko JK, Wong BC, Ye Y, Lam S, Cho C. 2001. Protective role of cyclooxygenase inhibitors in the adverse action of passive cigarette smoking on the initiation of experimental colitis in rats. Eur J Pharmacol 411(1-2):193-203.
22. Cuzzocrea S, Mazzon E, Serraino I, Dugo L, Centorrino T, Ciccolo A, Sautebin L, Caputi AP. 2001. Celecoxib, a selective cyclo-oxygenase-2 inhibitor reduces the severity of experimental colitis induced by dinitrobenzene sulfonic acid in rats. Eur J Pharmacol 431(1):91-102.
23. Topcu TY, Akpolat M, Uz YH, Kizilay G, Sapmaz-Metin M, Cerkezkayabekir A, Omurlu IK. 2013. Effects of curcumin on apoptosis and oxidoinflammatory regulation in a rat model of acetic acid-induced colitis: The roles of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase. J Med Food 16(4):296-305.
24. Liu L, Yuan S, Sun Y, Long Y, Li Y, Niu Y, Li C, Gan H, Cao S, Mei Q. 2009. The possible mechanisms of fructus mume pill in the treatment of colitis induced by 2, 4, 6-trinitrobenzene sulfonic acid in rats. J Ethnopharmacol 126(3):557-564.
25. Kakkar P, Das B, Viswanathan PN. 1984. Modified spectrophotometric assay of SOD. Ind J Biochem Biophys 21:130-132.
26. Romano M, Dri P, Dadalt L, Patriarca P, Baralle FE. 1997. Biochemical and molecular characterization of hereditary myeloperoxidase deficiency. Blood 90:4126-4134.
27. Ohkawa H, Ohishi N, Yagi K. 1979. Assay of lipid peroxidation in animal tissue by thiobarbituric acid reaction. Anal Biochem 95:351-358.
28. Dubey R, Dubey R, Omrey P, Vyas S P, Jain SK. 2010. Development and characterization of colon specific drug delivery system bearing 5- ASA and camylofine dihydrochloride for the treatment of ulcerative colitis. J Drug Target 18(8):589-601.
29. Paulson SK, Vaughn MB, Jessen SM, Lawal Y, Gresk CJ, Yan B, Maziasz TJ, Cook CS, Karim A. 2001. Pharmacokinetics of celecoxib after oral administration in dogs and humans: Effect of food and site of absorption. J Pharmacol Exp Ther 297(2):638-645.
30. Yang KY, Lin LC, Tseng TY, Wang SC, Tsai TH. 2007. Oral bioavailability of curcumin in rat and the herbal analysis from curcuma longa by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 853(1-2):183-189.
31. Yoo JW, Giri N, Lee CH. 2011. pH-Sensitive eudragit nanoparticles for mucosal drug delivery. Int J Pharm 403(1-2):262-267.
32. Wiebke U, Alf L. 2010. Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases. J R Soc Interface 7:S55-S66.
33. Nagashima R. 1981. Mechanisms of action of sucralfate. J Clin Gastroenterol 3:117-127.
34. Feng SS, Mu L, Chen BH, Pack D. 2002. Polymeric nanospheres fabricated with natural emulsifiers for clinical administration of an anticancer drug paclitaxel (Taxol®). Mat Sci Eng C 20:85-92.
35. Boughton-Smith NK, Wallace JL, Morris GP, Whittle BJ. 1988. The effect of anti-Inflammatory drugs on eicosanoid formation in a chronicmodel of inflammatory bowel disease in the rat. Br J Pharmacol 94(1):65-72.
36. Villegas I, Alarcon de la Lastra C, Orjales A, La Casa C. 2003. A new flavonoid derivative, dosmalfate, attenuates the development of dextran sulphate sodium-induced colitis in mice. Int Immunopharmacol 3(13-14):1731-1741.
37. Hasegawa H, Suzuki K, Nakaji S, Sugawara K. 1997. Analysis and assessment of the capacity of neutrophils to produce reactive oxygen species in a 96-well microplate format using lucigenin and luminol-dependent chemiluminescence. J Immunol Methods 210 (1):1-10.
38. Grisham MB. 1994. Oxidants and free radicals in inflammatory bowel disease. Lancet 344(8926):859-861.
39. Lamprecht A, Yamamoto H, Takeuchi H, Kawashima Y. 2005. A pH-sensitive microsphere system for the colon delivery of tacrolimus containing nanoparticles. J Control Release 104(2):337-346.